11 recruiting, 6 not yet recruiting, 1 active not recruiting, 1 terminated. 6 Phase 1, 3 Phase 2, 3 Phase 4, 2 Early Phase 1, 1 Not applicable.
Follow ANCA Associated Vasculitis (AAV): new trials by email Literature Review of ANCA Associated Vasculitis (AAV) trials Research Report on ANCA Associated Vasculitis (AAV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV. ANCA Associated Vasculitis (AAV) | Not yet recruiting | University of the West of England | 80 | 2026-10-01 | 2026-10-06 | |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-03-05 |
| PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis ANCA Associated Vasculitis (AAV) | Recruiting | University of Edinburgh | 120 | 2026-01-28 | 2026-02-12 | |
| CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases QT-019C - SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2026-01-01 | 2026-01-20 |
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Rituximab - ANCA Associated Vasculitis (AAV) | Phase 3 | Recruiting | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 300 | 2025-11-10 | 2026-08-13 |
| SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis Gliflozin - Lupus Nephritis (LN), ANCA Associated Vasculitis (AAV) | Phase 4 | Not yet recruiting | Federico II University | 40 | 2025-09-01 | 2025-06-25 |
| The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis CAR-T Therapy - ANCA Associated Vasculitis (AAV) | Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2025-07-01 | 2025-06-24 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases OL-108 - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) | Phase 1 | Recruiting | Beijing GoBroad Hospital | 44 | 2025-06-01 | 2025-05-20 |
| Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy Ex Vivo Assay - Rheumatic Diseases, Rheumatoid Arthritis (RA) | Recruiting | University of Bonn | 120 | 2025-04-01 | 2025-09-02 | |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases Anti-CD19 IL-10/IL15 CAR-NK - Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV) | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 15 | 2025-01-06 | 2025-12-29 |
| Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases RD06-05 CART Cell Injection - SLE, Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 18 | 2025-01-03 | 2026-02-02 |
| AYLo - AutoimmunitY and Loss of y Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array - Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR) | Recruiting | University of Bonn | 500 | 2024-11-15 | 2025-04-10 | |
| Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis Avacopan, prednisolone and rituximab, Prednisolone and rituximab - ANCA Associated Vasculitis (AAV) | Phase 4 | Recruiting | Chiba University | 160 | 2024-11-15 | 2025-05-04 |
| Rare AutoImmune SElf-management Programme Development Non-interventional study - Systemic Lupus Erthematosus, Systemic Vasculitis | Recruiting | University of the West of England | 360 | 2024-10-01 | 2024-10-15 | |
| IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy IMPT-514 CART Cell Injection - Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV) | Early Phase 1 | Terminated | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3 | 2024-06-13 | 2026-01-28 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (19) · Myositis (8) · Scleroderma, Systemic (7) · Lupus Erythematosus, Systemic (5) · Sjogren's Syndrome (4) · Antiphospholipid Syndrome (3) · Granulomatosis with Polyangiitis (3) · Microscopic Polyangiitis (3) · Vasculitis (3) · Arthritis, Psoriatic (2) · Arthritis, Rheumatoid (2) · Connective Tissue Diseases (2) · Giant Cell Arteritis (2) · Polymyalgia Rheumatica (2) · Systemic Vasculitis (2)
Cardiovascular Diseases (19) · Immune System Diseases (19) · Skin Diseases (19) · Skin Diseases, Vascular (19) · Skin and Connective Tissue Diseases (19) · Vascular Diseases (19) · Autoimmune Diseases (18) · Systemic Vasculitis (17) · Vasculitis (16) · Nervous System Diseases (11) · Connective Tissue Diseases (10) · Musculoskeletal Diseases (9) · Muscular Diseases (8) · Neuromuscular Diseases (8) · Arthritis (6)
Rituximab (3) · Azathioprine (1) · BDB001 (1) · Cyclophosphamide (1) · Flow Cytometry (1) · Glucocorticoids (1) · Immunotherapy, Adoptive (1) · Polymorphism, Single Nucleotide (1) · Prednisolone (1) · Prednisone (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · avacopan (1)
Peking University Third Hospital (2) · University of Bonn (2) · University of the West of England (2) · Assistance Publique - Hôpitaux de Paris (1) · Beijing GoBroad Hospital (1) · Chiba University (1) · Children's Hospital of Fudan University (1) · Federico II University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Nanjing Bioheng Biotech Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (9) · United Kingdom (4) · Germany (2) · Japan (2) · Brazil (1) · France (1) · Israel (1) · Saudi Arabia (1) · Singapore (1) · Switzerland (1) · United States (1)
Joanna Robson (1) · Masayoshi Harigai, MD, PhD (1) · Minghui Zhao, M.D. (1) · Neeraj Dhaun, MBChB PhD (1)
PMID 16142864, PMID 16987829, PMID 17471524, PMID 19054820, PMID 20360188, PMID 21109517, PMID 23045170, PMID 25479696, PMID 33596356, PMID 34061144, PMID 34133081, PMID 35110332, PMID 35110333, PMID 36927642, PMID 9041949
2025 (1)